恒瑞医药：四款药品获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating progress in its research and development pipeline [1]. Group 1 - The company announced on January 9 that it, along with its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd., has received clinical trial approval for SHR-4394, HRS-5041 tablets, SHR-2554 (Zemiglo), and Revlimid tablets [1]. - The clinical trials for these drugs are set to commence shortly, reflecting the company's ongoing commitment to expanding its product offerings and enhancing its market position [1].